Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Amortization of Deferred Charges (2018 - 2025)

Historic Amortization of Deferred Charges for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $126000.0.

  • Exagen's Amortization of Deferred Charges rose 60400.0% to $126000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $411000.0, marking a year-over-year increase of 12707.18%. This contributed to the annual value of $276000.0 for FY2024, which is 2396.69% down from last year.
  • Exagen's Amortization of Deferred Charges amounted to $126000.0 in Q3 2025, which was up 60400.0% from $53000.0 recorded in Q2 2025.
  • Over the past 5 years, Exagen's Amortization of Deferred Charges peaked at $164000.0 during Q4 2024, and registered a low of -$25000.0 during Q3 2024.
  • For the 5-year period, Exagen's Amortization of Deferred Charges averaged around $104052.6, with its median value being $132000.0 (2021).
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first tumbled by 13676.47% in 2024, then soared by 60400.0% in 2025.
  • Exagen's Amortization of Deferred Charges (Quarter) stood at $137000.0 in 2021, then rose by 2.19% to $140000.0 in 2022, then tumbled by 50.71% to $69000.0 in 2023, then soared by 137.68% to $164000.0 in 2024, then fell by 23.17% to $126000.0 in 2025.
  • Its Amortization of Deferred Charges was $126000.0 in Q3 2025, compared to $53000.0 in Q2 2025 and $68000.0 in Q1 2025.